Download PDF
Thromb Haemost 2005; 93(05): 816-819
DOI: 10.1160/TH05-01-0043
Rapid and Short Communication
Schattauer GmbH

Effect of plasminogen activator inhibitor-1 deficiency on nutritionally-induced obesity in mice

Roger H. Lijnen
1   Center for Molecular and Vascular Biology, KU Leuven, Belgium
› Author AffiliationsFinancial support: This study was supported by the “Bijzonder Onderzoeksfonds KU Leuven” (OT/03/48) and by the “Fonds voor Wetenschappelijk Onderzoek-Vlaanderen” (G.0112.02).
Further Information

Publication History

Received 20 January 2005

Accepted after revision 19 February 2005

Publication Date:
11 December 2017 (online)

    Permissions and Reprints

Summary

Plasminogen activator inhibitor-1 (PAI-1) is the main physiological inhibitor of tissue-type (t-PA) and urokinase-type (u-PA) plasminogen activator. Recent studies in murine models have yielded apparently conflicting data on a potential role of PAI-1 in adipose tissue development and obesity. To reinvestigate this issue, we have rederived PAI-1 deficient (PAI-1-/-) and wild-type (WT) mice and generated true littermates in a 81.25% C57Bl/6: 18.75% 129 SV genetic background. Male 5-week-old PAI-1-/- and WT mice were kept on a high fat diet (20.1 kJ/g) for 15 weeks. Body weight gain was comparable for both genotypes, and at the time of sacrifice total body weights (39 ± 1.1 versus 41 ± 1.2 g) as well as the weights of subcutaneous (SC, 1,520 ± 110 versus 1,480 ± 110 mg) adipose tissue were not significantly different. In contrast, the gonadal (GON, 1,900 ± 43 versus 1,510 ± 86 mg, p < 0.005) tissue mass was larger in PAI-1-/- mice. Plasma levels of insulin, leptin, glucose, triglycerides, total, HDL and LDL cholesterol were comparable for both genotypes. Immunohisto-chemical analysis of SC and GON adipose tissues did not reveal differences in adipocyte size or number between both genotypes, whereas blood vessel density was also comparable for GON fat but lower in SC fat of WT mice. Thus, this study in littermate mice on high fat diet did not reveal an effect of PAI-1 deficiency on body weight, and a differential effect on SC and GON adipose tissue.

Keywords

PAI-1 - obesity - adipose tissue - insulin
 

  • References

  • 1 Lijnen HR. Pleioptropic functions of plasminogen activator inhibitor-1. J Thromb Haemost 2005; 3: 35-45.
    CrossrefPubMedGoogle Scholar
  • 2 Gils A, Declerck PJ. The structural basis for the pathophysiological relevance of PAI-1 in cardiovascular diseases and the development of potential PAI-1 inhibitors. Thromb Haemost 2004; 91: 425-37.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Shimomura I, Funahashi T, Takahashi M. et al. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med 1996; 2: 800-3.
    CrossrefPubMedGoogle Scholar
  • 4 Samad F, Loskutoff DJ. Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice. Mol Med 1996; 2: 568-82.
    PubMedGoogle Scholar
  • 5 Alessi MC, Peiretti F, Morange P. et al. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 1997; 46: 860-7.
    CrossrefPubMedGoogle Scholar
  • 6 Alessi MC, Bastelica D, Morange P. et al. Plasminogen activator inhibitor 1, transforming growth factor-beta 1, and BMI are closely associated in human adipose tissue during morbid obesity. Diabetes 2000; 49: 1374-80.
    CrossrefPubMedGoogle Scholar
  • 7 Van Dielen FMH, Buurman WA, Hadfoune M. et al. Macrophage inhibitory factor, plasminogen activator inhibitor-1, other acute phase proteins, and inflammatory mediators normalize as a result of weight loss in morbidly obese subjects treated with gastric restrictive surgery. J Clin Endocrinol Metab 2004; 89: 4062-8.
    CrossrefPubMedGoogle Scholar
  • 8 Morange PE, Lijnen HR, Alessi MC. et al. Influence of PAI-1 on adipose tissue growth and on metabolic parameters in a murine model of diet-induced obesity. Arterioscler Thromb Vasc Biol 2000; 20: 1150-4.
    CrossrefPubMedGoogle Scholar
  • 9 Lijnen HR, Maquoi E, Morange P. et al. Nutritionally induced obesity is attenuated in trangenic mice overexpressing plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol 2003; 23: 78-84.
    CrossrefPubMedGoogle Scholar
  • 10 Eren M, Su M, Atkinson J. et al. Phenotypic derangements associated with overexpression of plas- minogen activator inhibitor-1 (PAI-1) in transgenic mice. Arterioscler Thromb Vasc Biol 2001; 21: 695 (Abstract).
    PubMedGoogle Scholar
  • 11 Schafer K, Fujisawa K, Konstantinides S. et al. Disruption of the plasminogen activator inhibitor 1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice. FASEB J 2001; 15: 1840-2.
    CrossrefPubMedGoogle Scholar
  • 12 Ma L-J, Mao S-L, Taylor KL. et al. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 2004; 53: 336-46.
    CrossrefPubMedGoogle Scholar
  • 13 Carmeliet P, Kieckens L, Schoonjans L. et al. Plasminogen activator inhibitor-1 gene-deficient mice: generation by homologous recombination and characterization. J Clin Invest 1993; 92: 2746-55.
    CrossrefPubMedGoogle Scholar
  • 14 Giles AR. Guidelines for the use of animals in biomedical research. Thromb Haemost 1987; 58: 1078-84.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Demeulemeester D, Collen D, Lijnen HR. Effect of matrix metalloproteinase inhibition on adipose tissue development. Biochem Biophys Res Comm 2005; 329: 106-11.
    PubMedGoogle Scholar
  • 16 Declerck PJ, Verstreken M, Collen D. Immunoassay of murine t-PA, u-PA and PAI-1 using monoclonal antibodies raised in gene-inactivated mice. Thromb Haemost 1995; 74: 1305-9.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 World Health Organization. Obesity: preventing and managing the global epidemic. 2000. Geneva: WHOTechnical Report Series; 894
    Google Scholar
  • 18 Isomaa B, Almgren P, Tuomi T. et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-9.
    CrossrefPubMedGoogle Scholar
  • 19 Lakka HM, Laaksonen DE, Lakka TA. et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-16.
    CrossrefPubMedGoogle Scholar
  • 20 Skurk T, Hauner H. Obesity and impaired fibrinolysis: role of adipose productionof plasminogen activator inhibitor-1Int. J Obes Relat Metab Disord 2004; 28: 1357-64.
    CrossrefPubMedGoogle Scholar
  • 21 Reaven CM. Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu Rev Med 1993; 44: 121-31.
    CrossrefPubMedGoogle Scholar
  • 22 Juhan-Vague I, Alessi M-C, Mavri A. et al. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost 2003; 1: 1575-9.
    CrossrefPubMedGoogle Scholar
  • 23 Coleman DL. Diabetes – obesity syndromes in mice. Diabetes 1982; 31: 1-6.
    CrossrefPubMedGoogle Scholar
  • 24 West DB, Boozer CN, Moody DL. et al. Dietary obesity in nine inbread mouse strains. Am J Physiol 1992; 262: R1025-32.
    PubMedGoogle Scholar
  • 25 Valet P, Tavernier G, Castan-Laurell I. et al. Understanding adipose tissue development from transgenic animal models. J Lipid Res 2002; 43: 835-60.
    PubMedGoogle Scholar
  • 26 Hoover-Plow J, Ellis J, Yuen L. In vivo plasminogen deficiency reduces fat accumulation. Thromb Haemost 2002; 87: 1011-9.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 Morange PE, Bastelica D, Bonzi MF. et al. Influence of t-PA and u-PA on adipose tissue development in a murine model of diet-induced obesity. Thromb Haemost 2002; 87: 306-10.
    Article in Thieme ConnectPubMedGoogle Scholar